000			02231 a2200577 4500
005			20250513233440.0
264		0	_c20010628
008			200106s 0 0 eng d
022			_a0889-8588
024	7		_a10.1016/s0889-8588(05)70204-5 _2doi
040			_aNLM _beng _cNLM
100	1		_aGarcia-Manero, G
245	0	0	_aSalvage therapy for refractory or relapsed acute lymphocytic leukemia. _h[electronic resource]
260			_bHematology/oncology clinics of North America _cFeb 2001
300			_a163-205 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aATP Binding Cassette Transporter, Subfamily B, Member 1 _xantagonists & inhibitors
650	0	4	_aAdult
650	0	4	_aAngiogenesis Inhibitors _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aBone Marrow Transplantation
650	0	4	_aCancer Care Facilities _xstatistics & numerical data
650	0	4	_aChild
650	0	4	_aChromosome Aberrations
650	0	4	_aClinical Trials as Topic
650	0	4	_aCombined Modality Therapy
650	0	4	_aDNA Methylation _xdrug effects
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aEnzyme Inhibitors _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aImmunophenotyping
650	0	4	_aMulticenter Studies as Topic
650	0	4	_aNeoplasm Proteins _xantagonists & inhibitors
650	0	4	_aOligonucleotides, Antisense _xtherapeutic use
650	0	4	_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy
650	0	4	_aProtein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aRecurrence
650	0	4	_aRemission Induction
650	0	4	_aRisk Factors
650	0	4	_aSalvage Therapy
650	0	4	_aSurvival Analysis
650	0	4	_aTexas _xepidemiology
650	0	4	_aTreatment Outcome
700	1		_aThomas, D A
773	0		_tHematology/oncology clinics of North America _gvol. 15 _gno. 1 _gp. 163-205
856	4	0	_uhttps://doi.org/10.1016/s0889-8588(05)70204-5 _zAvailable from publisher's website
999			_c11190324 _d11190324